The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The US Food and Drug Administration has approved the use of finerenone (Kerendia) in heart failure (HF) patients with mildly ...

Kerendia is a nonsteroidal mineralocorticoid receptor antagonist. Here’s how it treats chronic kidney disease.

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...

This morning, the German group revealed that mineralocorticoid receptor antagonist (MRA) Kerendia (finerenone) was able to reduce cardiovascular death and other heart failure events compared to ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for Kerendia (finerenone) to treat a new indication. The sNDA seeks ...

KERENDIA is a non-steroidal mineralocorticoid receptor antagonist (MRA) and was approved by the U.S. Food and Drug Administration (FDA) in July 2021 to reduce the risk of sustained eGFR decline ...

The FINEARTS-HF study, which compared Kerendia to a placebo when added to standard therapy, met its primary endpoint by reducing cardiovascular death and total heart failure events.